This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Diphtheria, tetanus, pertussis (3 component), poliomyelitis and haemophilus


Vaccine containing diphtheria, tetanus, pertussis (acellular component), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)

Drugs List

  • diphtheria & tetanus with pertussis (3 component) poliomyelitis & haemophilus influenzae B adsorbed vaccine
  • INFANRIX -IPV+Hib adsorbed vaccine
  • Therapeutic Indications


    Diphtheria - prophylaxis
    Immunisation against haemophilus influenzae type B invasive disease
    Pertussis - prophylaxis
    Poliomyelitis - prophylaxis
    Tetanus - prophylaxis

    Active primary and booster immunisation against diphtheria, tetanus, pertussis, poliomyelitis and invasive infections caused by haemophilus influenzae type B in infants and children from the age of 2 months.

    For comprehensive information or advice on this product or the immunisation programme in the UK, the following website should be accessed.


    Diphtheria, tetanus, pertussis, poliomyelitis and haemophilus influenzae type B vaccine should be administered in accordance with official recommendations and/or local practice, especially vaccinations given after the second year of life.


    Primary Immunisation
    Children aged over 10 years
    The current Department of Health recommendation is that vaccines containing a pertussis component should not be used routinely in children 10 years of age or older.

    Children aged 2 months and above
    Two or three single (0.5ml) doses should be administered with an interval of at least one month between doses. Infants who receive this combined vaccine for the first dose should receive the same vaccine for the second and third dose.

    Booster Dose
    Administer 0.5ml as a single dose.


    For intramuscular injection.

    The recommended injection site is the anterolateral aspect of the thigh.


    Children under 6 weeks
    Encephalopathy of unknown aetiology within 7 days previous pertussis vacc.
    Severe febrile conditions
    Uncontrolled epileptic disorder
    Uncontrolled neurological disorder

    Precautions and Warnings

    Children aged 6 weeks to 2 months
    History of post vaccination pyrexia above 40 degrees C within 48 hours
    Previous post vaccination convulsions within 3 days
    Previous post vaccination crying for over 3 hours within 48 hours
    Previous post vaccination shock like state within 48 hours
    History of neurological disorder
    Immunodeficiency syndromes
    Neurological disorder

    No protection against other strains of haemophilus influenzae or meningitis
    Postpone immunisation if there is active or suspected infection
    Impaired response possible in immunocompromised patients
    Not all available brands are licensed for all age groups
    Vaccine may not be effective in 100% of patients
    May contain polysorbate
    May contain trace amounts of neomycin
    May contain trace amounts of polymyxin
    Do not mix with other vaccines in the same syringe
    Inject other vaccines at different sites
    Pertussis vaccination not routinely recommended in patients over 10 years
    Resuscitation facilities must be immediately available
    Monitor patient for 2-3 days if history of febrile convulsions
    Risk of apnoea in premature infants - monitor respiration for 72 hours
    May interfere with diagnostic antigen tests for 2 weeks post vaccination
    Follow national immunisation guidelines

    Children with progressive, evolving or unstable neurological conditions (including seizures) should not be vaccinated until their condition is stabilised or corrected. The risk-benefit of immunising with this vaccine or deferring this vaccination should be weighed carefully in an infant or child suffering from a new onset or progression of a severe neurological disorder.

    A history of febrile convulsions, a family history of convulsions or Sudden Infant Death Syndrome do not constitute a contraindication for the use of this vaccine. Vaccinees with a history of febrile convulsions should be closely followed up as such adverse events may occur within 2 to 3 days post vaccination.

    Pregnancy and Lactation


    In the current vaccination schedule in the UK, this vaccination is not indicated for use in any patient of 10 years of age or older.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    In the current vaccination schedule in the UK, this vaccination is not indicated for use in any patient of 10 years of age or older.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Anaphylactic reaction
    Anaphylactoid reaction
    Angioneurotic oedema
    Decreased appetite
    Erythema at injection site
    Hypotonic hyporesponsive episode
    Induration (injection site)
    Limb swelling
    Local pain (injection site)
    Swelling (injection site)
    Upper respiratory tract infection
    Vesiculation (injection site)


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: June 2014

    Reference Sources

    Summary of Product Characteristics: Infanrix-IPV+Hib powder and suspension for suspension for injection. GlaxoSmithKline UK Ltd. Revised October 2013.

    Immunisation against infectious disease - The Green Book.
    Available at:
    Last accessed 24 June, 2014.

    NICE Evidence Services Available at: Last accessed: 27 June 2017

    Use of Infanrix-IPV+Hib in the infant immunisation schedule
    Available at:
    Last accessed: 24 June, 2014.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.